drugset
drugset / Trial / NCT04480697

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

NCT04480697 ↗

Phase 1 Completed 56 enrolled Hepagene (Shanghai) Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HPG1860 orally administered in healthy subjects.

Timeline

Start
2019-09-23
Primary completion
2020-11-25
Completion
2021-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HPG1860 Small molecule 10 mg Oral
Subject HPG1860 Small molecule 20 mg Oral
Subject HPG1860 Small molecule 30 mg Oral
Subject HPG1860 Small molecule 40 mg Oral
Subject HPG1860 Small molecule 80 mg Oral
Subject HPG1860 Small molecule 90 mg Oral
Subject HPG1860 Small molecule 120 mg Oral
Subject HPG1860 Small molecule 150 mg Oral

Indications

No indication recorded.